Inside Nephrology: A Weekly Review
Nefrologia
Advances in Renal-Cell Carcinoma and Prostate Cancer Diagnostics
This week's episode covers groundbreaking studies in renal-cell carcinoma treatment, prostate cancer diagnostics, and ECMO management, featuring research from leading experts in the field.
Bibliography
1. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Authors: Choueiri TK, Powles T, Burotto M, et al.
Journal: The New England journal of medicine, 2021 Mar 4
PMID: 33657295
DOI: 10.1056/NEJMoa2026982
2. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis.
Authors: Kasivisvanathan V, Rannikko AS, Borghi M, et al.
Journal: The New England journal of medicine, 2018 May 10
PMID: 29552975
DOI: 10.1056/NEJMoa1801993
3. A Randomized, Placebo-Controlled, Double-Blind, Crossover Trial of Inhaled Nitric Oxide in Patients With Mild-to-Severe COPD.
Authors: Collins SÉ, Kirby M, Smith BM, et al.
Journal: Chest, 2026 Jun
PMID: 41895703
DOI: 10.1016/j.chest.2026.01.012
4. Chronic inflammation in benign prostatic hyperplasia: Pathophysiology and treatment options.
Authors: Inamura S, Terada N
Journal: International journal of urology : official journal of the Japanese Urological Association, 2024 Sep
PMID: 38934050
DOI: 10.1111/iju.15518
5. Extracorporeal membrane oxygenation, acute kidney injury, fluid balance, and continuous renal replacement therapy: Acute Disease Quality Initiative (ADQI) and Extracorporeal Life Support Organization (ELSO) joint consensus conference.
Authors: Gist KM, Selewski DT, Kashani KB, et al.
Journal: Intensive care medicine, 2026 Jun
PMID: 42113209
DOI: 10.1007/s00134-026-08440-3
6. Hydrochlorothiazide and Prevention of Kidney-Stone Recurrence.
Authors: Dhayat NA, Bonny O, Roth B, et al.
Journal: The New England journal of medicine, 2023 Mar 2
PMID: 36856614
DOI: 10.1056/NEJMoa2209275
7. Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma.
Authors: Apolo AB, Ballman KV, Sonpavde G, et al.
Journal: The New England journal of medicine, 2025 Jan 2
PMID: 39282902
DOI: 10.1056/NEJMoa2401726
8. A double-blind, randomized, placebo-controlled, phase 2 trial examined the efficacy and safety of monlunabant in adults with diabetic kidney disease.
Authors: Cherney DZI, Bonefeld K, Crater G, et al.
Journal: Kidney international, 2026 Jun
PMID: 41866124
DOI: 10.1016/j.kint.2026.02.023
9. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Authors: Choueiri TK, Powles T, Burotto M, et al.
Journal: The New England journal of medicine, 2021 Mar 4
PMID: 33657295
DOI: 10.1056/NEJMoa2026982
10. Placebo in Paediatric Clinical Trials: Systematic Literature Review and Framework-Based Synthesis.
Authors: Parry G, Abelian A, Williams CCE, et al.
Journal: Journal of paediatrics and child health, 2026 Jun
PMID: 42046265
DOI: 10.1111/jpc.70399
Authors: Choueiri TK, Powles T, Burotto M, et al.
Journal: The New England journal of medicine, 2021 Mar 4
PMID: 33657295
DOI: 10.1056/NEJMoa2026982
2. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis.
Authors: Kasivisvanathan V, Rannikko AS, Borghi M, et al.
Journal: The New England journal of medicine, 2018 May 10
PMID: 29552975
DOI: 10.1056/NEJMoa1801993
3. A Randomized, Placebo-Controlled, Double-Blind, Crossover Trial of Inhaled Nitric Oxide in Patients With Mild-to-Severe COPD.
Authors: Collins SÉ, Kirby M, Smith BM, et al.
Journal: Chest, 2026 Jun
PMID: 41895703
DOI: 10.1016/j.chest.2026.01.012
4. Chronic inflammation in benign prostatic hyperplasia: Pathophysiology and treatment options.
Authors: Inamura S, Terada N
Journal: International journal of urology : official journal of the Japanese Urological Association, 2024 Sep
PMID: 38934050
DOI: 10.1111/iju.15518
5. Extracorporeal membrane oxygenation, acute kidney injury, fluid balance, and continuous renal replacement therapy: Acute Disease Quality Initiative (ADQI) and Extracorporeal Life Support Organization (ELSO) joint consensus conference.
Authors: Gist KM, Selewski DT, Kashani KB, et al.
Journal: Intensive care medicine, 2026 Jun
PMID: 42113209
DOI: 10.1007/s00134-026-08440-3
6. Hydrochlorothiazide and Prevention of Kidney-Stone Recurrence.
Authors: Dhayat NA, Bonny O, Roth B, et al.
Journal: The New England journal of medicine, 2023 Mar 2
PMID: 36856614
DOI: 10.1056/NEJMoa2209275
7. Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma.
Authors: Apolo AB, Ballman KV, Sonpavde G, et al.
Journal: The New England journal of medicine, 2025 Jan 2
PMID: 39282902
DOI: 10.1056/NEJMoa2401726
8. A double-blind, randomized, placebo-controlled, phase 2 trial examined the efficacy and safety of monlunabant in adults with diabetic kidney disease.
Authors: Cherney DZI, Bonefeld K, Crater G, et al.
Journal: Kidney international, 2026 Jun
PMID: 41866124
DOI: 10.1016/j.kint.2026.02.023
9. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Authors: Choueiri TK, Powles T, Burotto M, et al.
Journal: The New England journal of medicine, 2021 Mar 4
PMID: 33657295
DOI: 10.1056/NEJMoa2026982
10. Placebo in Paediatric Clinical Trials: Systematic Literature Review and Framework-Based Synthesis.
Authors: Parry G, Abelian A, Williams CCE, et al.
Journal: Journal of paediatrics and child health, 2026 Jun
PMID: 42046265
DOI: 10.1111/jpc.70399
